Latebreakers: Keppra gets another epilepsy indication

Patients six years of age and older with primary generalized tonic-clonic seizures can now use levetiracetam (Keppra, UCB) as an adjunctive therapy to treat their epilepsy. According to the manufacturer, levetiracetam is now approved to treat 80% of all seizure types, including partial-onset seizures in patients four years of age and older and myoclonic seizures in patients 12 years of age and older with juvenile myoclonic epilepsy. The IV formulation is approved for partial seizures as an alternative for adult patients when oral administration is temporarily not possible.